Merck, Inc.
🇺🇸United States
Treatment of Patients With Major Depressive Disorder With MK0869 (0869-066)(COMPLETED)
Phase 3
Completed
- Conditions
- Major Depressive Disorder
- First Posted Date
- 2002-05-03
- Last Posted Date
- 2017-04-26
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 900
- Registration Number
- NCT00034983
Treatment of Patients With Major Depressive Disorder With MK0869 (0869-059)
Phase 3
Completed
- Conditions
- Major Depressive Disorder
- First Posted Date
- 2002-05-03
- Last Posted Date
- 2017-04-18
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 468
- Registration Number
- NCT00035009
Treatment of Patients With Major Depressive Disorder With MK0869 (0869-068)(COMPLETED)
Phase 3
Completed
- Conditions
- Major Depressive Disorder
- First Posted Date
- 2002-05-03
- Last Posted Date
- 2017-05-05
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 540
- Registration Number
- NCT00035048
Treatment of Patients With Major Depressive Disorder With MK0869 (0869-063)
Phase 3
Completed
- Conditions
- Major Depressive Disorder
- First Posted Date
- 2002-05-03
- Last Posted Date
- 2017-05-05
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 495
- Registration Number
- NCT00034944
Treatment of Patients With Major Depressive Disorder With MK0869 (0869-061)
Phase 3
Completed
- Conditions
- Major Depressive Disorder
- First Posted Date
- 2002-05-03
- Last Posted Date
- 2017-04-18
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 584
- Registration Number
- NCT00035295
Treatment of Patients With Major Depressive Disorder With MK0869 (0869-060)(COMPLETED)
Phase 3
Completed
- Conditions
- Major Depressive Disorder
- First Posted Date
- 2002-05-03
- Last Posted Date
- 2015-02-09
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 450
- Registration Number
- NCT00035282
Study of Farnesyl Protein Transferase Inhibitor (FPTI) in Patients With Leukemia (Study P00701)
Phase 1
Completed
- Conditions
- LeukemiaMyelodysplastic SyndromesLeukemia, Myeloid, ChronicBlast CrisisLeukemia, Lymphocytic
- First Posted Date
- 2002-05-02
- Last Posted Date
- 2015-06-17
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 132
- Registration Number
- NCT00034684
Study of Posaconazole in the Treatment of Invasive Fungal Infections (Study P02095)
Phase 3
Completed
- Conditions
- Mycoses
- First Posted Date
- 2002-05-02
- Last Posted Date
- 2017-03-10
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Registration Number
- NCT00034632
Prophylaxis Trial in High Risk Allogenic Stem Cell Transplant Recipients With Graft vs. Host Disease
Phase 3
Completed
- Conditions
- Mycoses
- First Posted Date
- 2002-05-02
- Last Posted Date
- 2017-03-10
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 600
- Registration Number
- NCT00034645
Open Label Study of Posaconazole in the Treatment of Invasive Fungal Infections (Study P00041)
Phase 3
Completed
- Conditions
- Mycoses
- First Posted Date
- 2002-05-02
- Last Posted Date
- 2017-03-10
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 336
- Registration Number
- NCT00034658
© Copyright 2025. All Rights Reserved by MedPath